{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:59:17Z","timestamp":1790290757414,"version":"4.1.0"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2023,10,26]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Graves\u2019 ophthalmopathy is a complex autoimmune disorder that can significantly affect quality of life (QoL), vision and physical appearance. Recently, a deeper understanding of the underlying pathogenesis has led to the development of novel treatment options.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The purpose of this review is to explore the current literature on conventional and novel treatment modalities and to evaluate which interventions provide the most favourable psychological and clinical outcomes in patients with moderate to severe, active Grave\u2019s ophthalmopathy. For example, QoL is an important psychosocial outcome of disease management. However, available literature demonstrates that not all clinically effective treatment options improve patients\u2019 QoL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic literature review was conducted to assess the clinical and psychosocial outcomes of different therapies for Graves\u2019 ophthalmopathy. An extensive database search of Ovid Medline, Ovid Embase and Cochrane Central Register of Controlled Trials was conducted. Studies generated were reviewed and the relevant selected data were retrieved and analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Results showed intravenous steroids, rituximab (RTX), tocilizumab and teprotumumab were all significantly effective in improving Clinical Activity Scores. Orbital radiotherapy showed a slight improvement in proptosis and diplopia. All interventions were safe with few serious adverse events being reported across all studies. All treatment modalities demonstrated beneficial improvements in both components of the Graves\u2019 Ophthalmopathy-QoL (QoL) questionnaire, apart from orbital radiotherapy which only demonstrated improvements in the visual functioning subscale. Teprotumumab was identified to be the most effective intervention for improving both clinical and psychosocial outcomes. However, further research needs to be conducted to evaluate its side effect profile and cost-effectiveness. Nonetheless, with time it has the potential to be a first-line treatment option in the management of active moderate to severe Graves\u2019 ophthalmopathy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjophth-2023-001515","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T20:46:37Z","timestamp":1718657197000},"page":"e001515","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Graves\u2019 ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions \u2013 a systematic review"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-2880","authenticated-orcid":false,"given":"Oyinlola Maria","family":"Bello","sequence":"first","affiliation":[{"name":"Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK"},{"name":"Queen Mary University of London William Harvey Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maralyn","family":"Druce","sequence":"additional","affiliation":[{"name":"Queen Mary University of London William Harvey Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaz","family":"Ansari","sequence":"additional","affiliation":[{"name":"Canterbury Christ Church University Institute of Medical Sciences, Chatham, UK"},{"name":"Ophthalmology, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"2025090109101639000_9.1.e001515.1","first-page":"368","article-title":"Quality of life in patients with graves Ophthalmopathy","volume":"103","author":"Yeatts","year":"2005","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2025090109101639000_9.1.e001515.2","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2017.58.431"},{"key":"2025090109101639000_9.1.e001515.3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030809"},{"key":"2025090109101639000_9.1.e001515.4","first-page":"59","article-title":"To be a great physician, you must understand the whole story","volume":"9","author":"Centor","year":"2007","journal-title":"MedGenMed"},{"key":"2025090109101639000_9.1.e001515.5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01241.x"},{"key":"2025090109101639000_9.1.e001515.6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000508071","article-title":"Predictive factors for changes in quality of life after steroid treatment for active moderate-to-severe graves' Orbitopathy: A prospective trial","volume":"9","author":"Hoppe","year":"2021","journal-title":"Eur Thyroid J"},{"key":"2025090109101639000_9.1.e001515.7","doi-asserted-by":"crossref","unstructured":"Bartalena L , Krassas G , Wiersinga WM , et al . Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate-Tosevere and active graves' Orbitopathy (GO): a multicenter, randomized, Doubleblind clinical study of 159 patients. Eur Thyroid J 2012;1. doi:10.1159\/000339890","DOI":"10.1159\/000339890"},{"key":"2025090109101639000_9.1.e001515.8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a Multicentre, 2 X 2 factorial, double-blind, randomised controlled trial","volume":"6","author":"Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025090109101639000_9.1.e001515.9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1089\/thy.2014.0037","article-title":"What are the Psychosocial outcomes of treatment for thyroid eye disease? A systematic review","volume":"24","author":"Wickwar","year":"2014","journal-title":"Thyroid"},{"key":"2025090109101639000_9.1.e001515.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"2025090109101639000_9.1.e001515.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.038"},{"key":"2025090109101639000_9.1.e001515.12","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.6.377"},{"key":"2025090109101639000_9.1.e001515.13","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European group on graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves' Orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2025090109101639000_9.1.e001515.14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014"},{"key":"2025090109101639000_9.1.e001515.15","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1111\/aos.15074","article-title":"Comparative effectiveness of different treatment modalities for active, moderate-to-severe graves' Orbitopathy: a systematic review and network meta-analysis","volume":"100","author":"Li","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"2025090109101639000_9.1.e001515.16","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab034","article-title":"Thyroid eye disease: navigating the new treatment landscape","volume":"5","author":"Dosiou","year":"2021","journal-title":"J Endocr Soc"},{"key":"2025090109101639000_9.1.e001515.17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety of very low-dose Rituximab in patients with graves' Orbitopathy","volume":"31","author":"Vannucchi","year":"2021","journal-title":"Thyroid"},{"key":"2025090109101639000_9.1.e001515.18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with Rituximab in patients with active moderate to severe graves' Orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"2025090109101639000_9.1.e001515.19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4274\/tjo.80688","article-title":"Thyroid-associated Ophthalmopathy","volume":"47","author":"\u015eahl\u0131","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"2025090109101639000_9.1.e001515.20","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated Ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090109101639000_9.1.e001515.21","doi-asserted-by":"crossref","unstructured":"Da P , S R . The limitations of QALY: a literature review. J Stem Cell Res Ther 2016;06. doi:10.4172\/2157-7633.1000334","DOI":"10.4172\/2157-7633.1000334"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2023-001515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:10:24Z","timestamp":1756743024000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2023-001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/bmjophth-2023-001515"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2023-001515","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}